We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




RT-PCR Assay Developed to Detect Bloodstream Infections

By LabMedica International staff writers
Posted on 11 Jun 2018
Rapid detection and identification of a causative pathogen is essential in the treatment of critically ill patients with blood stream infection (BSI), since timely initiation of adequate antibiotic treatment is associated with decreased morbidity, mortality, and possibly reduced healthcare costs.

Conventional culture of inoculated blood samples, termed blood culture (BC), is currently considered the “gold standard” for diagnosing BSI. More...
However, its diagnostic accuracy may be hampered by concomitant antibiotic treatment, low levels of circulating bacteria, and poor sensitivity for slow growing, intracellular, and fastidious microorganisms.

Scientists at the University of Utrecht Medical Center (Utrecht, the Netherlands) and their colleagues collected 5 mL of blood from critically ill patients across multiple years for both blood culture and polymerase chain reaction (PCR) testing. They used 347 blood-culture positive samples, representing up to 50 instances for each pathogen covered by the assay, as well as 200 blood-culture negative samples in order to compare PCR results. After sample collection, the team added a buffer solution and performed centrifugation on the samples, isolating 7 mL to 10 mL of pathogen DNA per sample for PCR testing.

The team designed three novel multiplex assays in order to detect specific pathogens at the species level, as well as an additional broad PCR assay, called molecular Gram stain, to discriminate clinically relevant Gram-negative specimens from Gram-positive specimens. Bacterial pathogens included Escherichia coli, Enterococcus faecium, E. faecalis, Acinetobacter baumannii, and Staphylococcus aureus. In addition, the researchers included probes for Candida species, Aspergillus, and the resistance markers mecA and CTX- M1,9.

The blood stream infection (BSI-PCR) assays were run on a LightCycler system. Bacterial species-specific PCR sensitivities ranged from 65% to 100%. Sensitivity was 26% for the Gram-positive PCR, 32% for the Gram-negative PCR, and ranged 0% to 7% for yeast PCRs. Yeast detection was improved to 40% in a smaller set-up. There was no overall association between BSI-PCR sensitivity and time-to-positivity of BC (which was highly variable), yet Ct-values were lower for true-positive versus false-positive PCR results. False-positive results were observed in 84 (4%) of the 2,200 species-specific PCRs in 200 culture-negative samples, and ranged from 0% to 6% for generic PCRs.

The authors concluded that that there was no overall link between BSI-PCR sensitivity and time to positivity of blood culture. Overall, they believe that sensitivity of the BSI-PCR is promising for individual bacterial pathogens, but still inadequate for yeasts and generic PCRs. The study was originally published online on April 26, 2018, in the European Journal of Clinical Microbiology and Infectious Diseases.

Related Links:
University of Utrecht Medical Center


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
POC Immunoassay Analyzer
Procise DX
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.